久久精品在线视频-久久精品在这里-久久精品这里-久久精品这里精品-久久精品这里热有精品-久久精品这里热有精品2015

BioChain Engineering Research System  

for Key Technologies in the Prevention and Control of Chronic Diseases

Engineering R&D drives high-tech innovations, constructing a comprehensive solution for the “Triple E*” approach to chronic diseases.

Based on innovative liquid biopsy technology, BioChain has established a strategic research framework with the aim of developing proprietary methodologies for the early detection, diagnosis, and intervention (hereinafter referred to as “Triple E*”) of  chronic diseases such as cancer, cardiovascular disease, and cerebrovascular disease. Our research center comprises seven medical engineering research laboratories, including Epigenetics, Multi-omics Integration, Transcription, Proteomics, Bioinformatics, Automation, and Material Engineering laboratories. These laboratories provide guidance and assistance in applying and transforming clinical outcomes.

Proprietary Technologies

Sample Processing Technology

BioChain has developed the industry's first automated equipment for nucleic acid extraction and purification. It includes cell lysis, nucleic acid extraction and purification, and bisulfite conversion on a single automated platform. It can significantly reduces the testing time by 60% when compared to manual operation.

Liquid Biopsy Technology

BioChain offers a wide range of proprietary cfDNA extraction and laboratory preparation kits. Our cfDNA extraction kit can be used with various sample types, such as blood, plasma, and urine. It also delivers 20% higher extraction purity and efficiency compared to high-quality products in the market. Our laboratory preparation kit also uses a single-stranded cfDNA laboratory preparation method for methylation sequencing. Its optimal sequencing depth is 77% higher than other industry-leading products when the same amount of cfDNA is used.

Biomarker Discovery Technology

BioChain primarily integrates Whole Genome Bisulfite Sequencing (WGMS) and Next Generation Sequencing (NGS) methylation-specific panels to ensure sufficient sequencing coverage of cancer-related genes and to distinguish genome-wide methylation levels. A high-efficiency biomarker discovery procedure is achieved when it is combined with self-developed AI interpretation and standardized validation systems.

Pan-Cancer Early Detection

Our current service for the six high-risk cancers in China (lung, colorectal, gastric, esophageal, liver, and thyroid cancers) requires only 10 mL of peripheral blood and has an overall sensitivity, specificity, and tumor tissue-of-origin agreement rate of up to 91.0%, 95.3%, and 85.9%, respectively.(Data as of July 2023)

Artificial Intelligence (AI) Interpretation Technology

BioChain has built a high-performance computing (HPC) cluster with a computing capacity of over 200 trillion operations per second. Combined with its algorithm system, it can seamlessly execute quality control, sequence alignment, feature extraction, and other processes of high-throughput sequencing data, and build multi-dimensional comprehensive models. At present, BioChain has obtained more than ten exclusive algorithm patents related with the Multidimensional and Omics Data Integration Algorithm (MODE).

Industrialization Platform

BioChain has established an advanced industrialization platform and adheres strictly to the ISO13485 Quality Management System. With this approach, the company effectively executes all process stages, including project approval, product development, performance validation, production transfer, preclinical research, registration testing, clinical trials, registration declaration, and marketing authorization. In addition, BioChain operates an industrialization base covering almost 40,000 square meters in the Beijing Economic-Technological Development Area (BDA), enabling it to provide testing products and services to millions of individuals annually.

BioChain Pipeline

As a leader in the “Triple E*” approach to tackling chronic diseases,  BioChain started with a strong focus on gastrointestinal (GI) cancers and has now gradually expanded into dozens of other cancers, as well as other major diseases such as cardiovascular and cerebrovascular diseases.

主站蜘蛛池模板: 在线播放国产精品 | 成人a毛片高清视频 | 不卡在线视频 | 亚洲精品毛片久久久久久久 | 亚洲国产精品久久久久666 | 欧美三级aaa | 日本中文字幕视频在线看 | 午夜剧j | 天天视频入口 | 久久爱avwww久久爱 | 日韩毛片免费 | 四虎最新紧急入口4hu | 手机看片福利盒子久久 | 手机看黄av免费网址 | 玖玖精品视频 | 亚洲欧美国产一区二区三区 | 99久久这里只精品国产免费 | 国产精品免费一级在线观看 | 婷婷夜夜躁天天躁人人躁 | 成人网18免费网站在线 | 国产成人精品本亚洲 | 亚洲精品久久久久久婷婷 | 99国产精品免费视频观看 | 国产福利精品在线观看 | 日本中文字幕一区二区高清在线 | 中文字幕在线观看一区二区三区 | 四虎国产精品永久地址99新强 | 国产级a爱做片免费观看 | 国产精品久久福利新婚之夜 | 一级一片免费播放 | 亚洲色视频在线播放网站 | 亚洲性生活视频 | 一级韩国aa毛片免费观看 | 国产精品视频ccav | 久久网站免费 | 亚洲精品成人久久 | 桃子在线观看 | 欧美成人 一区二区三区 | 亚洲欧美精品日韩欧美 | 欧美综合一区 | 久久伊人成人 |